Revista de farmacocinética y terapéutica experimental

Abstracto

Dalfampridine: Review Analysis on Multiple Sclerosis and Parkinson?s disease related to Waking Disability

Taslim Shaikh

The Multiple sclerosis and Parkinson’s disease are neurodegenerative disease which effect on the central nervous system. Which loss the coordination between brain and body multiple sclerosis is the progressive, autoimmune disease. It occurs when your immune system attack myelin cell in your brain and spinal cord. Parkinson’s disease is caused by the loss of dopamine in a part of your brain called substantial nigra, which causes and cure are unknown. MS disease are commonly occurs in young adult i.e. 20to 40 years where as Parkinson’s disease commonly occurs in old persons i.e. 60 years. Both the disease do not occur in same person, both disease loss the coordination of brain and body related to gait dysfunction. Dalfampridine is one of the available treatments for to improve the walking in MS and Parkinson’s disease related to gait dysfunction. Dalfampridine is the oral potassium channel blocker which was recently approved by FDA for sympathomimetic treatment in MS. Dalfampridine which acts on central and peripheral nervous system enhances conduction in demyelinated axon and improves waking ability of MS patient.